{'52WeekChange': -0.3315218,
 'SandP52WeekChange': 0.0644362,
 'address1': '32 Wiggins Avenue',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 36.76,
 'askSize': 1000,
 'averageDailyVolume10Day': 97150,
 'averageVolume': 150382,
 'averageVolume10days': 97150,
 'beta': 1.179271,
 'beta3Year': None,
 'bid': 35.65,
 'bidSize': 800,
 'bookValue': 20.686,
 'category': None,
 'circulatingSupply': None,
 'city': 'Bedford',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 36.27,
 'dayLow': 35.44,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': 0.285,
 'enterpriseToEbitda': 10.281,
 'enterpriseToRevenue': 3.498,
 'enterpriseValue': 438204064,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '781-305-9720',
 'fiftyDayAverage': 35.724285,
 'fiftyTwoWeekHigh': 75.72,
 'fiftyTwoWeekLow': 22.01,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 13304405,
 'forwardEps': 1.16,
 'forwardPE': 30.75,
 'fromCurrency': None,
 'fullTimeEmployees': 154,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.040430002,
 'heldPercentInstitutions': 0.99609,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/anikatherapeutics.com',
 'longBusinessSummary': 'Anika Therapeutics, Inc., together with its '
                        'subsidiaries, provides orthopedic medicines for '
                        'patients with degenerative orthopedic diseases and '
                        'traumatic conditions in the United States and '
                        'internationally. The company develops, manufactures, '
                        'and commercializes therapeutic products based on its '
                        'proprietary hyaluronic acid (HA) technology. Its '
                        'orthobiologics products comprise ORTHOVISC, ORTHOVISC '
                        'mini, MONOVISC, and CINGAL for the treatment of '
                        'osteoarthritis of the knee; HYALOFAST, a '
                        'biodegradable support for human bone marrow '
                        'mesenchymal stem cells used for cartilage '
                        'regeneration and as an adjunct for microfracture '
                        'surgery; HYALONECT, a resorbable knitted fabric mesh; '
                        'HYALOSS MATRIX, HYAFF fibers used to mix blood/bone '
                        'grafts to form a paste for bone regeneration; and '
                        'HYALOGLIDE, an ACP gel used in tenolysis treatment. '
                        "The company's dermal products include wound care "
                        'products that comprise HYALOMATRIX and HYALOFILL for '
                        'the treatment of complex wounds, such as burns and '
                        'ulcers, and for use in connection with the '
                        'regeneration of skin; and ELEVESS, an aesthetic '
                        'dermatology product. Its surgical products comprise '
                        'HYALOBARRIER, a post-operative adhesion barrier for '
                        'use in the abdomino-pelvic area; MEROGEL, a woven '
                        'fleece nasal packing; and MEROGEL INJECTABLE, a '
                        'viscous hydrogel. The company also offers ophthalmic '
                        'products, including injectable HA products that are '
                        'used as viscoelastic agents in ophthalmic surgical '
                        'procedures, such as cataract extraction and '
                        'intraocular lens implantation; and veterinary '
                        'products, which include HYVISC, an injectable HA '
                        'product for the treatment of joint dysfunction in '
                        'horses. The company was founded in 1983 and is '
                        'headquartered in Bedford, Massachusetts.',
 'longName': 'Anika Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 506596000,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_328641',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 28479000,
 'nextFiscalYearEnd': 1640908800,
 'open': 36.27,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -72.94,
 'phone': '781-457-9000',
 'previousClose': 36.47,
 'priceHint': 2,
 'priceToBook': 1.7243545,
 'priceToSalesTrailing12Months': 4.043581,
 'profitMargins': 0.22732,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 36.27,
 'regularMarketDayLow': 35.44,
 'regularMarketOpen': 36.27,
 'regularMarketPreviousClose': 36.47,
 'regularMarketPrice': 36.27,
 'regularMarketVolume': 85674,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 14202300,
 'sharesPercentSharesOut': 0.14850001,
 'sharesShort': 2109139,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2049523,
 'shortName': 'Anika Therapeutics Inc.',
 'shortPercentOfFloat': 0.17629999,
 'shortRatio': 14.18,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'ANIK',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 1.979,
 'trailingPE': 18.024254,
 'twoHundredDayAverage': 36.309063,
 'volume': 85674,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.anikatherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '01730'}